IP Library › Granted Patent US 10,513,724
Granted Patent B2
US 10,513,724 · App. 15/327,448 · Granted Dec 24, 2019

Production of glycoproteins with mammalian-like N-glycans in filamentous fungi

Inventors: Jari Natunen (Vantaa, FI); Anne Leppänen (Vantaa, FI); Heidi Salminen (Espoo, FI); Jukka Hiltunen (Helsinki, FI); Anne Kanerva (Helsinki, FI); Annamari Heiskanen (Helsinki, FI); Ann Westerholm-Parvinen (Kirkkonummi, FI); Georg Schmidt (Nahkela, FI); Anne Huuskonen (Helsinki, FI); Eero Mustalahti (Helsinki, FI); Christopher Landowski (Helsinki, FI); Markku Saloheimo (Helsinki, FI); Juhani Saarinen (Helsinki, FI); Benjamin Patrick Sommer (Basel, CH); Ramon Wahl (Basel, CH); Christian Ostermeier (Basel, CH); Bernhard Helk (Basel, CH)
Assignee: GLYKOS FINLAND OY
C12P21/005C12N9/1051C12N9/1081C12N9/2402C12Y204/99C12Y204/99018C12Y302/01024C12Y302/01113
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,513,724
App. No.
15/327,448
Granted
Dec 24, 2019
Kind
B2
Abstract

The present disclosure relates to compositions and methods useful for the production of recombinant glycoproteins in filamentous fungal cells, such as Trichoderma cells, wherein at least 90% (mol %), preferably at least 95% of the total neutral N-glycans of said produced recombinant glycoprotein are mammalian-like N-glycans. More specifically, the invention provides a filamentous fungal cell comprising i. one or more mutations that reduces or eliminates one or more endogenous protease activity compared to a parental filamentous fungal cell which does not have said mutation(s); ii. a polynucleotide encoding a heterologous catalytic subunit of oligosaccharyl transferase; iii. a recombinant polynucleotide for increasing α1, 2 mannosidase activity;and, iv. a recombinant polynucleotide encoding said heterologous glycoprotein.

Claims (39)

1. A Trichoderma or Myceliophthora filamentous fungal cell which produces a human antibody comprising mammalian-like neutral N-glycans, the Trichoderma or Myceliophthora filamentous fungal cell comprising:

i. one or more mutations that reduces or eliminates one or more endogenous protease activity compared to a parental Trichoderma or Myceliophthora filamentous fungal cell which does not have said mutation(s) and wherein endogenous protease is selected from the group consisting of aspartic proteases, trypsin-like serine proteases, subtilisin proteases, glutamic proteases, aminopeptidase proteases, sep proteases, and sedolisin proteases;

ii. a polynucleotide encoding a heterologous catalytic subunit of oligosaccharyl transferase;

iii. a mutation in the gene encoding dolichyl-P-Man:Man(5)GIcNAc(2)-PPdolichyl mannosyltransferase (ALG3) that eliminates the corresponding ALG3 expression compared to the level of expression of ALG3 gene in a parental Trichoderma or Myceliophthora cell which does not have such mutation,

iv. recombinant polynucleotide for expression of at least 2 distinct genes encoding a-glucosidase II, where the α-glucosidase II is selected from the group consisting of an, α recombinant polynucleotide encoding a Trichoderma α-glucosidase II, a recombinant polynucleotide encoding an Aspergillus α-glucosidase II catalytic domain, a recombinant polynucleotide encoding a microalgae α-glucosidase II catalytic domain, and a recombinant polynucleotide encoding a Trypanosoma α-glucosidase II catalytic domain,

v. a recombinant polynucleotide encoding an N-acetylglucosaminyltransferase I (GnTI) catalytic domain,

vi. a recombinant polynucleotide encoding an N-acetylglucosaminyltransferase II (GnTII) catalytic domain,

vii. a recombinant polynucleotide for increasing α1, 2 mannosidase activity; and,

viii. a recombinant polynucleotide encoding said human antibody,

wherein at least 90% (mol %), or at least 95% (mol %), of the total neutral N-glycans of said human antibody are Man3, GlcNAcMan3, G0, G1, G2, FG0, FG1 and/or FG2 glycoform, and less than 10% of the total neutral N-glycans of said human antibody are Hex6 glycoform, wherein Hex6 has structure of FIG. 1 .

2. The Trichoderma or Myceliophthora filamentous fungal cell of claim 1 , wherein the total protease activity is reduced to 40% or less, or 6% or less, of the total protease activity of the corresponding parental Trichoderma or Myceliophthora filamentous fungal cell in which the proteases do not have the reduced activity.

3. The Trichoderma or Myceliophthora filamentous fungal cell of claim 1 , which comprises a mutation in a protein O-mannosyltransferase (PMT) gene that reduces endogenous O-mannosyltransferase activity compared to a parental Trichoderma or Myceliophthora filamentous fungal cell which does not have said mutation.

4. The Trichoderma or Myceliophthora filamentous fungal cell of claim 1 , which is deficient in outer CHain elongation (OCH1) activity and/or Endo-N-acetyl-beta-D-glucosaminidase (EndoT) activity.

5. The Trichoderma or Myceliophthora filamentous fungal cell of claim 1 , wherein said catalytic subunit of oligosaccharyl transferase is a Leishmania oligosaccharyl transferase catalytic subunit.

6. A method for producing a human antibody with mammalian-like N-glycans, in a Trichoderma or Myceliophthora filamentous fungal host cell, said method comprising:

i. providing a Trichoderma or Myceliophthora filamentous fungal cell according to claim 1 ,

ii. culturing said Trichoderma or Myceliophthora filamentous fungal cell to produce said human antibody, and,

iii. isolating said human antibody.

7. The method of claim 6 , wherein at least 90% (mol %), or at least 95% (mol %), of the total neutral N-glycans of the mammalian-like N-glycans of said human antibody are G0, G1, G2, FG0, FG1 and/or FG2 glycoform.

8. The method of claim 6 , wherein said human antibody is selected from the group consisting of an antibody, an immunoglobulin, a protein fusion comprising an Fc fragment of an immunoglobulin, and a glycosylated antigen-binding fragment thereof.

9. A human antibody obtainable by the method of claim 1 .

10. A method for producing a Trichoderma or Myceliophthora filamentous fungal cell which produces a human antibody comprising mammalian-like neutral N-glycans, the method comprising:

i. introducing one or more mutations into the Trichoderma or Myceliophthora filamentous fungal cell that reduces or eliminates one or more endogenous protease activity compared to a parental Trichoderma or Myceliophthora filamentous fungal cell which does not have said mutation(s) and wherein endogenous protease is selected from the group consisting of aspartic proteases, trypsin-like serine proteases, subtilisin proteases, glutamic proteases, aminopeptidase proteases, sep proteases, and sedolisin proteases;

ii. introducing a polynucleotide encoding a heterologous catalytic subunit of oligosaccharyl transferase into the Trichoderma or Myceliophthora filamentous fungal cell;

iii. introducing a mutation in the gene encoding dolichyl-P-Man:Man(5)GlcNAc(2)-PPdolichyl mannosyltransferase (ALG3) that eliminates the corresponding ALG3 expression compared to the level of expression of ALG3 gene in a parental Trichoderma or Myceliophthora cell which does not have such mutation,

iv. recombinant polynucleotide for expression of at least 2 distinct genes encoding a-glucosidase II, where the α-glucosidase II is selected from the group consisting of an, α recombinant polynucleotide encoding a Trichoderma α-glucosidase II, a recombinant polynucleotide encoding an Aspergillus α-glucosidase II catalytic domain, a recombinant polynucleotide encoding a microalgae α-glucosidase II catalytic domain, and a recombinant polynucleotide encoding a Trypanosoma α-glucosidase II catalytic domain,

v. introducing a polynucleotide encoding an N-acetylglucosaminyltransferase I (GnTI) catalytic domain into the Trichoderma or Myceliophthora filamentous fungal cell,

vi. introducing a polynucleotide encoding an N-acetylglucosaminyltransferase II catalytic domain into the Trichoderma or Myceliophthora filamentous fungal cell,

vii. optionally, introducing a recombinant polynucleotide encoding a α1,6 fucosyltransferase activity and a recombinant polynucleotide encoding a GDP fucose synthesizing activity,

viii. introducing a recombinant polynucleotide for increasing α1,2 mannosidase activity into the Trichoderma or Myceliophthora filamentous fungal cell; and,

ix. introducing a recombinant polynucleotide encoding said human antibody into the Trichoderma or Myceliophthora filamentous fungal cell;

wherein at least 90% (mol %), or at least 95% (mol %), of the total neutral N-glycans of said human antibody are Man3, GIcNAcMan3, G0, G1, G2, FG0, FG1 and/or FG2 glycoform, and less than 10% of the total neutral N-glycans of said human antibody are Hex6 glycoform, wherein Hex6 has structure of FIG. 1 .

11. The Trichoderma or Myceliophthora filamentous fungal cell of claim 1 , wherein the recombinant nucleotide for increasing α1,2 mannosidase activity is an endogenous α1,2 mannosidase.

12. The Trichoderma or Myceliophthora filamentous fungal cell of claim 1 , wherein the recombinant nucleotide for increasing α1,2 mannosidase activity is T. reesei α1,2 mannosidase or Myceliophthora thermophila α1,2 mannosidase.

13. The Trichoderma or Myceliophthora filamentous fungal cell of claim 1 , wherein the Trichoderma or Myceliophthora cell further comprises a recombinant polynucleotide encoding a α1,6 fucosyltransferase activity and a recombinant polynucleotide encoding a GDP fucose synthesizing activity.

14. The Trichoderma or Myceliophthora filamentous fungal cell of claim 13 , wherein the GDP fucose synthesizing activity comprises GDP-mannose-4,6 dehydratase (GMD) activity and GDP-4-keto-6-deoxy-D-mannose-3,5-epimerase/4-reductase (FX) activity.

15. The Trichoderma or Myceliophthora filamentous fungal cell of claim 1 , wherein the yield of the human antibody is at least 0.5 grams per liter.

16. The Trichoderma or Myceliophthora filamentous fungal cell of claim 1 , wherein N-glycosylation site occupancy is at least 95%.

17. The Trichoderma or Myceliophthora filamentous fungal cell of claim 1 , wherein less than 7%, less than 5%, less than 3%, less than 1% or less than 0.5% of the total neutral N-glycans of said human antibody are Hex6 glycoform of FIG. 1 .

Priority Claims (1)
EP 14177875 · Jul 21, 2014 · regional
Continuity (1)
Related Publication 20170159094A1 · Jun 8, 2017